Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer

Oncology

Volumn 57, Issue 4, 1999, Pages 318-323

  Nakanishi, Yoichi ^a   Kawasaki, Masayuki ^a   Bai, Fen ^a   Takayama, Koichi ^a   Pei, Xin Hai ^a   Takano, Koichi ^a   Inoue, Koji ^a   Osaki, Sin Ichi ^a   Hara, Nobuyuki ^a   Kiyohara, Chikako ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cisplatin; Glutathione S transferase ; Non small cell lung cancer; p53; Transbronchial biopsy

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TRANSBRONCHIAL BIOPSY;

EID: 0032703199     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012068     Document Type: Article

References (34)

1. Ginsgerg RJ, Vokes EE, Raben A: Non-small cell lung cancer, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott, 1997, pp 858-911.
2. Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B, Fatati G: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 1991;9:1453-1461.
3. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wison KS, Latreille J, Wierzbicki RF, Hill DP: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-641.
4. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675-679.
5. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: A frequent target for genetic abnormalities in lung cancer. Science 1986;246:491-494.
6. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74: 957-967.
7. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R, Takahashi T: Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancer. J Clin Oncol 1996;14:497-502.
8. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-2291.
9. Nabeya Y, Loganzo F Jr, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP: The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1994;64:1-10.
10. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-5042.
11. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N: The utility of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res 1997;3:1195-1200.
12. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N: Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 1998;34:1352-1257.
13. Meister A: Glutathione metabolism and its selective modification. J Biol Chem 1988;263: 17205-17208.
14. Moscow JA, Townsend AJ, Cowan KH: Elevation of π class glutathione S-transferase activity in human breast cancer cells by transfection of the GST-π gene and its effect on sensitivity to toxins. Mol Pharmacol 1989;36:22-28.
15. Armstrong DK, Gordon GB, Hilton J, Streeper RT, Colvin OM, Davidson NE: Hepsulfam sensitivity in human breast cancer cell lines: The role of glutathione and glutathione S-transferase in resistance. Cancer Res 1992;52:1416-1421.
16. Nakanishi Y, Matsuki A, Takayama K, Yatsunami J, Kawasaki M, Abe M, Hara N: Glutathione derivatives enhance adriamycin cytotoxicity in a human lung adenocarcinoma cell line. Anticancer Res 1997;17:2129-2134.
17. Howie AF, Forrester LM, Glancey MJ, Schlager JJ, Powis G, Beckett GJ, Hayes JD, Wolf CR: Glutathione S-transferase and glutathione peroxidase expression in normal and tumor human tissues. Carcinogenesis 1990;11:451-458.
18. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M, Sugimachi K: Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 1994;74:1230-1236.
19. Bai F, Nakanishi Y, Kawasaki M, Takayama K, Yatsunami J, Pei XH, Tsuruta N, Wakamatsu K, Hara N: Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 1996;78: 416-421.
20. Mountain CF: A new international classification system for lung cancer. Chest 1986; 89(suppl 1):225-233.
21. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979, WHO Offset No 48.
22. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R, Takahashi T: Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancer. J Clin Oncol 1996;14:497-502.
23. Eimoto H, Tsutsumi M, Nakajima A, Yamamoto K, Takashima Y, Maruyama H, Konishi Y: Expression of the glutathione S-transferase placental form in human lung carcinomas. Carcinogenesis 1988;9:2325-2327.
24. SAS Institute: SAS/STAT User's Guide, release 6.03 edition, Cary, USA.
25. Stewart LA, Pignon JP, Parmer MKB, Le Chevalier RL, Souhami RL, NSCLC Collaborators Group: A meta-analysis using individual patient data from randomized clinical trials of chemotherapy in non-small cell lung cancer: Survival in the supportive setting (abstract 1118). Proc Am Soc Clin Oncol 1994;13:337.
26. von Hoff DD; Clark GM, Stogelill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF: Prospective clinical trial of a human tumor cloning system. Cancer Res 1983;43:1926-1931.
27. Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH: Chemotherapy testing of human solid tumors. Cancer 1984;53:1240-1245.
28. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
29. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.
30. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study. J Clin Oncol 1997;15:1916-1922.
31. Hirazono K, Shinozuka T, Kuroshima Y, Itoh H, Kawai K: Immunohistochemical expression of glutathione S-transferase π (GST-π) and chemotherapy response in malignant ovarian tumors. J Obstet Gynaecol 1995;21:305-312.
32. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST-π. Br J Cancer 1997;74:1458-1465.
33. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-609.
34. Feld R, Abratt R, Graziano S, Jassem J, Lacquet L, Ninane V, Paesmans M, Rocmans P, Schiepers C, Stahel R, Stephens R: Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 1997;17(suppl 2):3-10.